Blog

This Week in European MedTech and HealthTech: 3rd July 2026 A quieter week on the deal front as Europe entered the summer window, but one defined by a single towering story: Alan's €480 million Series G, which crowned the French prevention-insurance platform as Europe's most valuable private HealthTech company at €5.5 billion. Beneath it, the market's K-shaped recalibration continued, AI-native platforms commanding premium valuations while legacy digital health incumbents reprice and the countdown to the EU AI Act's 2nd August high-risk obligations entered its final month.Funding &amp; Expansion Alan (France) confirmed a €480M Series G at a €5.5B post-money valuation, led by Prosus with participation from existing backers Index Ventures and Teachers' Venture Growth, plus new investor Dara Holdings. The digital health insurer and care platform passed €800M ARR in Q1 2026 (+53% YoY), serves 1.1M+ members and is profitable in France. Capital funds European expansion and its push to make "prevention insurance" a global standard. Notably, this comes just ~90 days after a €100M primary raise at €5.0Bn, a €500M valuation step-up inside a quarter. EIT Health (26th June) opened new funding calls for high-potential European SMEs building solutions across biotech, MedTech, digital health, AI and diagnostics, a useful non-dilutive route for earlier-stage companies in a selective venture market. NHS North East &amp; North Cumbria awarded £1.5M in WorkWell funding to six health innovations, part of a steady drip of regional NHS innovation capital. A thin week for announced private rounds overall, consistent with the H1 pattern of fewer, larger deals: Q1 2026 saw $1.2B deployed across European digital health at a $21.1M average deal size, with capital concentrating in late-stage category leaders.The AI Narrative: AI-Native Premium vs. Legacy Repricing The week's defining tension sat inside two French companies. Alan attributes its ability to scale revenue 53% with limited headcount growth to an AI-native operating model, and Prosus's cheque is as much a bet on that operating leverage as on insurance economics. Meanwhile, Doctolib's ~40% secondary-market devaluation (from a €5.8B 2022 peak to ~€3.6B) continued to reverberate as the reference point for European HealthTech repricing, a reminder that secondary prices, higher cost of capital and normalised post-pandemic growth are resetting expectations for even the strongest franchises. Doctolib itself is playing offence, with its acquisition of London-based Medicus and £100M+ UK primary care investment plan progressing.For founders and boards, the read-through: the market is not rewarding "digital health" as a category, &nbsp;it is rewarding demonstrable AI-driven operating leverage, clinical validation and profitable unit economics. Everything else is repricing.Regulatory &amp; Market Access EU AI Act — one month to go. The majority of high-risk AI obligations enter into application on 2nd August 2026. Critically for MedTech, Article 6(1), covering AI embedded in CE-marked devices requiring Notified Body conformity assessment under MDR/IVDR, &nbsp;is deferred to August 2027, giving device manufacturers an extra year, while standalone high-risk AI systems face the 2026 deadline. Parallel compliance confirmed. The political agreement on the Digital Omnibus amending the AI Act keeps AI-enabled medical devices under dual AI Act + MDR/IVDR compliance rather than sector-specific rules alone. MedTech Europe has called this "an unnecessary layer of complexity", with industry estimates of up to €3.3B per year in compliance cost. Notified Body reform bedding in. Implementing Regulation 2026/977 (adopted 4 May) is now standardising Notified Body conformity assessment procedures, timelines and cost estimates under MDR/IVDR, a genuine, if incremental, improvement to Europe's certification bottleneck, alongside the Commission's broader MDR simplification proposal. UK: MHRA builds its AI runway. The MHRA has confirmed a dedicated regulatory framework for AI as a Medical Device in 2026 (per the Life Sciences Sector Plan), is expanding its AI sandbox model across medicines and devices, and launched London Region I, &nbsp;a regulatory sandbox with NHS England for controlled deployment of AI medical devices in live NHS settings. M&amp;A &amp; Partnerships Note No major European MedTech M&amp;A printed this week, though H1 2026 medtech deal value reached $36.5B and 2026 M&amp;A is tracking at a decade-high pace, with AI "tuck-in" acquisitions expected to accelerate in H2. In the NHS market, Joined Up Care Derbyshire signed a 10-year shared care record contract with Orion Health, a reminder that long-dated NHS platform contracts remain among the most valuable recurring-revenue assets in UK HealthTech.Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.ukNelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ https://www.healthcare.digital&nbsp;Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb&nbsp;Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTlloyd@nelsonadvisors.co.ukpaul@nelsonadvisors.co.ukMeet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

This Week in European MedTech and HealthTech: 3rd July 2026

The European healthcare technology and services landscape has entered a structurally distinct phase of maturation, transitioning from the speculative, growth-at-all-costs venture capital paradigms of the post-pandemic era into an era defined by profitable efficiency, clinical validation and platform scale.&nbsp; &nbsp;&nbsp; Following several years of valuation corrections and capital constraints, mergers and acquisitions have become the dominant, necessary exit route for maturing enterprises, consistently and overwhelmingly outperforming initial public offerings by volume.&nbsp; &nbsp;&nbsp; Within this overarching consolidation wave, venture-to-venture "tuck-in" transactions, where late-stage, well capitalised digital health scale-ups acquire early-stage, highly specialised startups, have experienced a marked acceleration.&nbsp; This shift represents a strategic pivot away from funding isolated, single-purpose point solutions and toward the integration of robust, multi-product enterprise platforms capable of delivering quantifiable clinical and operational returns to overstretched health systems.Click here to read the report <a href="https://www.healthcare.digital/single-post/venture-to-venture-m-a-strategic-consolidation-in-european-healthtech-and-medtech">https://www.healthcare.digital/single-post/venture-to-venture-m-a-strategic-consolidation-in-european-healthtech-and-medtech</a>

Strategic Consolidation in European Healthtech and Medtech: An Analytical Assessment of Venture-to-Venture Tuck In Trends

Executive Summary &nbsp;&nbsp; The first half of 2026 confirmed the thesis we set out last December: European HealthTech and MedTech are transitioning from a volume-driven market into a value-driven one. Fewer companies are being funded, but the survivors are being funded harder; fewer deals are being signed, but the ones that close are larger, more strategic and increasingly organised around a single question, who owns defensible, clinically validated artificial intelligence.&nbsp; &nbsp;&nbsp; We enter the second half of the year with a market that is quieter on the surface and structurally more active underneath. &nbsp;&nbsp; Our headline call for H2 2026 is that the “bigger cheques, fewer bets” dynamic accelerates. We expect European digital health venture funding to remain well below its 2021–2022 peak in deal count, while average round sizes continue to climb and late-stage capital concentrates in a narrow band of category leaders.&nbsp; &nbsp;&nbsp; On the M&amp;A side, we anticipate a busier second half than first, driven by strategic carve-outs, private-equity buy-and-build platforms, and incumbents using their balance sheets and compliance infrastructure to acquire innovation they can no longer afford to build slowly. The regulatory picture, meanwhile, has shifted in a way that materially changes deal timing, and we think most market participants have not yet fully priced it in. &nbsp;&nbsp; This report sets out ten predictions across capital markets, M&amp;A, artificial intelligence, regulation, sub-sectors, private equity and geography, followed by the principal risks to our view and the strategic actions we believe founders, acquirers and sponsors should take before year-end. &nbsp;&nbsp; The H1 2026 Backdrop &nbsp;&nbsp; Any credible forecast has to start from where the market actually is, and the numbers from the first quarter frame the picture cleanly. European digital health venture funding reached roughly $1.2 Billion across 67 deals in Q1 2026, a decline of around 44% in capital deployed and 46% in deal count against the same period in 2025. On its own that reads as a market in retreat. But the average deal size rose to approximately $21 million, up 8% year-on-year and three mega-rounds of $100 Million or more closed in the quarter, led by Oviva’s $235 Million Series D, Alan’s $116 Million Series G and DentalMonitoring’s $100 Million Series D.&nbsp; &nbsp;&nbsp; This is not a market that has run out of capital; it is a market that has become far more selective about where capital goes. The exit environment tells a complementary story. Thirteen European exit transactions in Q1 2026 carried roughly $552 million in disclosed value, led by Kaia Health at $285 Million and Gleamer at $267 Million. Patient Solutions captured the largest share of new capital at around $298 Million, with Medical Diagnostics close behind and cardiovascular, diabetes and nutrition-focused ventures attracting the deepest therapeutic funding.&nbsp; &nbsp;&nbsp; The signal is consistent: money is flowing to categories with clear reimbursement pathways, demonstrable clinical outcomes and a credible route to either scaled commercialisation or strategic exit. &nbsp;&nbsp; The broader market context remains genuinely large. Europe’s digital health market generated an estimated $130 Billion in revenue in 2025 and is projected to compound at roughly 10% annually toward $314 Billion by 2034, while the European HealthTech market specifically is forecast to grow at an 18% CAGR from around $97 Billion in 2025 toward $222 Billion by 2030. Underneath a soft funding headline sits a structurally expanding end-market. That gap between subdued private financing and robust underlying demand is precisely the condition under which strategic and sponsor acquirers move and it is the foundation for most of what follows.Click here to read the report <a href="https://www.healthcare.digital/single-post/halfway-through-2026-nelson-advisors-predictions-on-what-s-to-come-in-european-healthtech-and-medte">https://www.healthcare.digital/single-post/halfway-through-2026-nelson-advisors-predictions-on-what-s-to-come-in-european-healthtech-and-medte</a>

Nelson Advisors predictions on what’s to come in European HealthTech and MedTech in H2 2026

Europe has quietly become one of the most productive regions on earth for building health and medical technology companies of genuine scale. Over the past decade a cohort of founders has turned the continent's structural disadvantages, fragmented markets, multiple regulators, conservative public payers, slow procurement, into the very foundations of durable, defendable businesses. This guide examines ten of them in depth. The companies profiled here are deliberately varied. They span pure software platforms (Doctolib, Ada Health, Kry/Livi), deep-science instrumentation (Oxford Nanopore), surgical robotics (CMR Surgical), applied genomics and AI biology (SOPHiA GENETICS, Owkin), clinical-AI infrastructure (Corti), tech-enabled care delivery (Cera) and preventive consumer medicine (Neko Health). Between them they have raised well over five billion euros from grants, venture capital, private equity, strategic pharmaceutical partners and the public markets. Some are now profitable; several are not; one cautionary comparator in this report went bankrupt after a multi-billion-dollar valuation. &nbsp; Three themes run through every case.&nbsp; First, the most defendable moats in European health technology are built not from clever algorithms but from proprietary data, regulatory clearance and entrenchment in the workflows of clinicians and payers, assets that take years to accumulate and are extremely hard to copy.&nbsp; &nbsp;&nbsp; Second, the distinction between being “AI-native” and an “AI enabler” matters far less than founders assume: what matters is whether AI is layered on top of a genuine distribution and data advantage.&nbsp; &nbsp;&nbsp; Third, the 2022–24 funding winter separated the survivors from the casualties almost entirely on the basis of capital discipline and proximity to whoever actually pays for healthcare. &nbsp;&nbsp; This is not a ranking. It is a working reference for founders and boards: a set of strategies, tactics, funding journeys, critical decisions and hard-won lessons drawn from companies that have already walked the path you are on. Read it as a map of what has worked, what has nearly killed otherwise excellent businesses, and where the genuinely defensible value in this market sits in 2026. &nbsp; How to read this guide▸ Each case study opens with a fact box (HQ, founders, funding, valuation, AI posture) followed by analysis of strategy, scalability, moat, risks, critical decisions and lessons.▸ Funding figures are drawn from company announcements and reputable reporting to mid-2026; private valuations are last-round marks and may be stale. Treat them as directional, not audited.▸ Cross-cutting chapters after the case studies synthesise the patterns: AI-native versus AI-enabler, moat construction, the funding map, and the risks that have sunk well-capitalised peers. &nbsp;&nbsp; The 2026 landscape: why these lessons matter now &nbsp;&nbsp; Founders entering HealthTech and MedTech in 2026 face a market that looks superficially similar to 2021 but behaves completely differently. The exuberant capital of the pandemic era has gone; in its place is a more demanding investor base that wants evidence of clinical impact, a credible path to profitability and a defensible position before it writes large cheques. At the same time, the underlying demand has never been stronger. Ageing populations, chronic disease burden, workforce shortages across European health systems and the maturation of artificial intelligence have combined to make health one of the few categories where technology can simultaneously cut cost and improve outcomes. &nbsp;&nbsp; The opportunity is therefore real, but the bar is higher. The companies in this report succeeded not because they rode a hype cycle but because they solved a structural problem for a payer, a clinician or a patient and then made that solution progressively harder to displace. Understanding how they did it and where comparable companies failed, is the single most useful preparation a founder can do. &nbsp;&nbsp; A simple framework: scalable, sustainable, defendable &nbsp;&nbsp; Throughout this guide we assess each company against three properties that, in our advisory work, separate enduring health-technology businesses from those that raise large rounds and then stall. &nbsp;&nbsp; • &nbsp; &nbsp; Scalable — can the business add revenue faster than it adds cost? Software platforms scale through near-zero marginal cost; hardware and care businesses scale through repeatable unit models, manufacturing capacity or acquisition roll-ups. The question is always: what is the unit, and does the next unit get cheaper? &nbsp;&nbsp; • &nbsp; &nbsp; Sustainable — does the business have a route to funding itself? In a market where reimbursement is slow and capital is expensive, the survivors are those with recurring revenue, demonstrated unit economics and the discipline to reach profitability before the money runs out. &nbsp;&nbsp; • &nbsp; &nbsp; Defendable — once the business works, how hard is it to copy? In health the durable moats are proprietary longitudinal data, regulatory clearance, entrenchment in clinical workflows, patent estates and trusted brand. Features are not moats; the assets that take years to build are. &nbsp; With that framework in mind, we turn to the ten companies. &nbsp;&nbsp; Why these ten companies &nbsp;&nbsp; These ten were not chosen as a definitive ranking of the best European health-technology companies, nor as an investment recommendation. They were selected because, between them, they illustrate the full range of strategies, business models, funding paths and moats a founder is likely to consider, also because each has progressed far enough to offer real, tested lessons rather than early promise. &nbsp;&nbsp; The selection deliberately spans the spectrum from pure software to deep science. Doctolib, Ada Health and Kry/Livi represent software-led platforms and digital care. Oxford Nanopore and CMR Surgical represent capital-intensive deep-science hardware. SOPHiA GENETICS and Owkin sit at the data-and-AI layer of genomics and drug discovery. Corti represents pure clinical-AI infrastructure. Cera represents technology-enabled care delivery, and Neko Health represents consumer-facing preventive medicine. The set also spans the funding journey, from companies still private and venture-backed, through those that took strategic capital from industry partners, to two that have weathered the public markets — and several European geographies, with companies anchored in France, the United Kingdom, Switzerland, Germany, Sweden and Denmark. &nbsp;&nbsp; Just as importantly, the cohort spans outcomes. Some are profitable; several are not; valuations have risen for some and fallen sharply for others. We have resisted the temptation to present only unambiguous successes, because the most useful lessons frequently lie in the tensions, a brilliant business with a punished share price, a category creator still searching for profitability, an AI pioneer confronting a new paradigm. Read together, they form a more honest map of the territory than a list of winners would.Click here to read the report in full <a href="https://www.healthcare.digital/single-post/the-nelson-advisors-guide-for-founders-to-healthtech-and-medtech-success-in-2026-10-european-case-s">https://www.healthcare.digital/single-post/the-nelson-advisors-guide-for-founders-to-healthtech-and-medtech-success-in-2026-10-european-case-s</a>

Nelson Advisors Guide for Founders to HealthTech and MedTech Success in 2026: 10 European Case Studies

The persistent productivity puzzle within the United Kingdom remains a major structural challenge for economists, academic institutions, and policymakers. While the British economy excels at spawning startups, transition rates from early-stage micro-enterprises to scaling, mid-market companies have historically been constrained by a pronounced management and leadership support gap. This barrier is particularly challenging in highly technical, regulated, and capital-intensive sectors such as life sciences, biotechnology, medtech, and healthtech, where long research and development cycles, complex clinical validation pathways, and talent acquisition hurdles compound the difficulties of scaling. &nbsp;&nbsp; To bridge this critical growth deficit, the Goldman Sachs 10,000 Small Businesses (10KSB) UK programme has acted as a vital educational and strategic intervention since its launch in 2010. Fully funded by the Goldman Sachs Foundation, the initiative provides high-growth small business leaders and social entrepreneurs with 100 hours of practical business and management education. Developed by leading experts, the curriculum is delivered in partnership with top-tier academic institutions, including Saïd Business School at the University of Oxford, the Aston Centre for Growth at Aston University, Leeds University Business School at the University of Leeds, and the Manchester Metropolitan University Business School. &nbsp;&nbsp; By targeting decision-makers of companies operating for at least three years with 5 to 50 employees and annual revenues exceeding £250,000, the programme provides the structural tools necessary to design and execute a robust, customized Business Growth Plan. An analysis of health-related business success stories within this framework shows how targeted business education helps scientific and clinical founders scale their companies, navigate market challenges, and create high-value employment. &nbsp;&nbsp; Longitudinal Economic Impact and the 10KSB Programme Effect &nbsp;&nbsp; The macroeconomic contribution of the 10KSB UK programme has expanded considerably over its fifteen-year history. Evaluations conducted by the Enterprise Research Centre (ERC) demonstrate that programme graduates achieve significantly higher rates of job creation, revenue generation, and productivity growth compared to matched control groups of similar size, age, and sector.Sectoral Success Stories in the Life Sciences, Medtech and Healthtech &nbsp;&nbsp; The practical application of the 10KSB curriculum is best demonstrated through the growth of specific companies in the life sciences, medtech, and healthtech fields. These firms have successfully converted business training into scalable clinical and commercial operations. &nbsp;&nbsp; CatSci: Transitioning from Catalyst Screening to Global Drug DevelopmentJune Medical: Scaling Medtech Manufacturing through Operational Excellence Principle Healthcare: Internationalising Nutraceutical ManufacturingConcierge Medical: Systematising Rural Private Healthcare Delivery Myonex: Rebranding and Scaling Global Clinical Trial Supply ChannelsAda Jabaru and Nistad Limited: Healthcare Compliance, Care Delivery and Community AdvocacyClick here to read the post in full <a href="https://www.healthcare.digital/single-post/scaling-healthcare-innovation-life-sciences-medtech-and-healthtech-success-stories-from-the-goldma">https://www.healthcare.digital/single-post/scaling-healthcare-innovation-life-sciences-medtech-and-healthtech-success-stories-from-the-goldma</a> &nbsp; &nbsp;

#10KSBUK Scaling Healthcare Innovation: Life Sciences, MedTech and HealthTech Success Stories from the Goldman Sachs 10,000 Small Businesses UK Programme

Healthcare markets outlook: A “dynamic” landscape ripe for M&amp;A deals and cross-border partnerships June 26, 2026. In spite of macro uncertainty, dealmaking in healthcare remains active, with capital following differentiated innovation, scalable platforms, resilient business models and, of course, AI.Here are 10 key points from J.P. Morgan's mid-year 2026 healthcare outlook: 1. &nbsp; &nbsp; M&amp;A and capital markets remain robust despite macro uncertainty, with capital flowing toward differentiated innovation, scalable platforms, resilient business models and AI. Strategic urgency — driven by patent cliffs, pipeline gaps and strong pharma balance sheets — is the core fuel. 2. &nbsp; &nbsp; Biopharma/biotech is leading dealmaking, with companies making strategic acquisitions to replenish pipelines. JPM cites Gilead's ~$5bn acquisition of Tubulis (next-gen antibody-drug conjugates) — the largest-ever European private, clinical-stage oncology sell-side deal. 3. &nbsp; &nbsp; Megadeals are back. Sun Pharma's $11.75bn acquisition of Organon was the year's largest biopharma deal, pairing two financially strong companies to expand Sun's Innovative Medicines business. 4. &nbsp; &nbsp; Financial sponsors are increasingly active. Thoreau's acquisition of Ensemble (revenue-cycle managed services) was the largest sponsor-to-sponsor transaction globally across all industries in 2026. 5. &nbsp; &nbsp; Cross-border activity is rising as companies reach further afield for innovation — e.g., GN Store Nord's hearing division merging with Italy's Amplifon, and Italy's Angelini Pharma acquiring US-based Catalyst Pharmaceuticals ($4.1bn) in rare neuromuscular diseases. 6. &nbsp; &nbsp; China is emerging as an innovation hub. JPM highlights rapid emergence of high-quality, cost-effective Chinese innovation pipelines, driving more out-licensing and partnership models with global pharma. 7. &nbsp; &nbsp; AI has shifted from experimentation to a real driver of capital allocation, becoming a core component of product strategy across diagnostics, imaging, clinical decision support, patient monitoring and precision medicine. The question has moved from "can AI create value" to "how fast can companies incorporate it." 8. &nbsp; &nbsp; Companies are buying AI rather than building it — acquiring AI-native businesses for proprietary data, algorithms and capabilities (e.g., CareDX/Naveris, Waystar/Iodine Software, Performant/Machinify). AI is also reaching back-office functions like claims, reimbursement and revenue-cycle automation. 9. &nbsp; &nbsp; A more complex policy and regulatory environment is reshaping strategy. Facing pricing pressure and market-access challenges, companies use M&amp;A for execution certainty (e.g., Alkermes/Avadel) while taking a disciplined approach to portfolio management via divestitures, carve-outs and take-privates (e.g., Baxter divesting Vantive Kidney Care, Select Medical going private). 10. &nbsp;Supply chain resilience is a strategic priority. Tariffs, energy costs and other shocks are pushing companies to diversify sourcing, invest in advanced manufacturing and integrate vertically — aligned with JPM's $1.5 trillion, 10-year Security and Resiliency Initiative, of which pharma and healthtech form an entire pillar.Source: <a href="https://www.jpmorgan.com/insights/banking/investment-banking/healthcare-mid-year-outlook">https://www.jpmorgan.com/insights/banking/investment-banking/healthcare-mid-year-outlook</a>

Nelson Advisors

Blog

This Week in European MedTech and HealthTech: 3rd July 2026

Strategic Consolidation in European Healthtech and Medtec...

Nelson Advisors predictions on what’s to come in European...

Nelson Advisors Guide for Founders to HealthTech and MedT...

#10KSBUK Scaling Healthcare Innovation: Life Sciences, Me...

10 Key Takeaway’s from J.P. Morgan's Mid 2026 Healthcare ...